- Home
- CANG vs ESPR Comparison
CANG vs ESPR Comparison
Compare CANG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- ESPR
- Stock Information
- Founded
- CANG 2010
- ESPR 2008
- Country
- CANG Hong Kong
- ESPR United States
- Employees
- CANG N/A
- ESPR N/A
- Industry
- CANG Computer Software: Prepackaged Software
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- ESPR Health Care
- Exchange
- CANG Nasdaq
- ESPR Nasdaq
- Market Cap
- CANG 811.9M
- ESPR 660.1M
- IPO Year
- CANG 2018
- ESPR 2013
- Fundamental
- Price
- CANG $1.52
- ESPR $4.00
- Analyst Decision
- CANG Strong Buy
- ESPR Buy
- Analyst Count
- CANG 1
- ESPR 7
- Target Price
- CANG $8.00
- ESPR $6.86
- AVG Volume (30 Days)
- CANG 649.4K
- ESPR 7.4M
- Earning Date
- CANG 12-01-2025
- ESPR 11-06-2025
- Dividend Yield
- CANG N/A
- ESPR N/A
- EPS Growth
- CANG N/A
- ESPR N/A
- EPS
- CANG N/A
- ESPR N/A
- Revenue
- CANG $396,289,992.00
- ESPR $303,802,000.00
- Revenue This Year
- CANG $4,386.58
- ESPR $18.83
- Revenue Next Year
- CANG $18.40
- ESPR N/A
- P/E Ratio
- CANG N/A
- ESPR N/A
- Revenue Growth
- CANG 495.15
- ESPR 2.83
- 52 Week Low
- CANG $1.16
- ESPR $0.69
- 52 Week High
- CANG $9.66
- ESPR $4.02
- Technical
- Relative Strength Index (RSI)
- CANG 22.63
- ESPR 75.37
- Support Level
- CANG $1.16
- ESPR $2.66
- Resistance Level
- CANG $3.73
- ESPR $3.26
- Average True Range (ATR)
- CANG 0.20
- ESPR 0.23
- MACD
- CANG -0.08
- ESPR 0.11
- Stochastic Oscillator
- CANG 14.01
- ESPR 98.18
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.